Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





TB-Related Articles										Related Pages
										Return to Main Menu**2018 DTBE Publications**
Althomsons SP, Hill AN, Harrist AV, France AM, Powell KM, Posey JE, Cowan LS, Navin TR. Statistical Method to Detect Tuberculosis Outbreaks among Endemic Clusters in a Low-Incidence Setting. Emerg Infect Dis.external icon 2018 Mar;24(3):573-575. doi: 10.3201/eid2403.171613. PMID: 29460749.
Aslam MV, Owusu-Edusei K, Marks SM, Asay GRB, Miramontes R, Kolasa M, Winston CA, Dietz PM. Number and cost of hospitalizations with principal and secondary diagnoses of tuberculosis, United States.external icon Int J Tuberc Lung Dis. 2018 Dec 1;22(12):1495-1504. doi: 10.5588/ijtld.18.0260. PMID: 30606323.Year202120202019201820172016201520142013Beavers SF, Pascopella L, Davidow AL, Mangan JM, Hirsch-Moverman YR, Golub JE, Blumberg HM, Webb RM, Royce RA, Buskin SE, Leonard MK, Weinfurter PC,Belknap RW, Hughes SE, Warkentin JV, Welbel SF, Miller TL, Kundipati SR, Lauzardo M, Barry PM, Katz DJ, Garrett DO, Graviss EA, Flood JM; Tuberculosis Epidemiologic Studies Consortium. Tuberculosis Mortality in the United States: Epidemiology and Prevention Opportunities.external icon Ann Am Thorac Soc. 2018 Feb 28. doi: 10.1513/AnnalsATS.201705-405OC. [Epub ahead of print]. PMID: 29490150.
Bigogo G, Cain K, Nyole D, Masyongo G, Auko JA, Wamola N, Okumu A, Agaya J, Montgomery J, Borgdorff M, Burton D. Tuberculosis case finding using population-based disease surveillance platforms in urban and rural Kenya.external icon BMC Infect Dis. 2018 Jun 7;18(1):262. doi: 10.1186/s12879-018-3172-z. PMID: 29879917.
Brown-Elliott BA, Simmer PJ, Trovato A, Hyle EP, Droz S, Buckwalter SP, Borroni E, Branda JA, Iana E, Mariottini A, Nelson J, Matteelli A, Toney NC, Scarparo C, de Man TJB, Vasireddy R, Gandhi RT, Wengenack NL, Cirillo DM, Wallace RJ, Tortoli E. Mycobacterium decipiens sp. nov., a new species closely related to the Mycobacterium tuberculosis complex.external icon Int J Syst Evol Microbiol. 2018 Sep 11. doi: 10.1099/ijsem.0.003031. [Epub ahead of print]. PMID: 30204586.
CDC (Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, Yelk Woodruff R, Allen L, LoBue P, Vernon, A.) Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent *Mycobacterium tuberculosis* Infection. MMWR 2018 June 29; 67(25);723–726.
CDC (Lardizabal AA, Khan AN, Bamrah Morris S, Goswami ND.) Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis — United States, 2017. MMWR 2018 September 7; 67(35);996–997.
CDC (Stewart RJ, Tsang CA, Pratt RH, Price SF, Langer AJ.) Tuberculosis — United States, 2017. MMWR 2018 March 23; 67(11);317–323.
Cherng ST, Shrestha S, Reynolds S, Hill AN, Marks SM, Kelly J, Dowdy DW. Tuberculosis Incidence Among Populations at High Risk in California, Florida, New York, and Texas, 2011-2015.external icon Am J Public Health. 2018 Nov;108(S4):S311-S314. doi: 10.2105/AJPH.2018.304503. PMID: 30383419.
Chorba T, Breedlove B. Concurrent conflicts—The Great War and the 1918 influenza pandemic [Note]. Emerg Infect Dis. 2018;24:1968–9.
Chorba T. Peace, liberty, mycobacteria, and tuberculosis mortality. Emerg Infect Dis. 2018;24:611–2.
Chorba T. Trench conflict with combatants and infectious disease [Note]. Emerg Infect Dis. 2018;24:2136–7.
Click ES, Murithi W, Ouma GS, McCarthy K, Willby M, Musau S, Alexander H, Pevzner E, Posey J, Cain KP. Detection of Apparent Cell-free M. tuberculosis DNA from Plasma.external icon Sci Rep. 2018 Jan 12;8(1):645. doi: 10.1038/s41598-017-17683-6. PMID: 29330384.
Click ES, Ouma GS, DeGruy K, Murithi W, Okonji JA, McCarthy KD, Musau S, Okumu A, Alexander H, Posey J, Cain KP. No evidence of *Mycobacterium tuberculosis* in breast milk of 18 women with confirmed TB disease in Kisumu, Kenya. Int J Tuberc Lung Dis.external icon 2018 Apr 1;22(4):464-465. doi: 10.5588/ijtld.17.0375. PMID: 29562997.
Cohn DL, El Sadr WM, Abrams DI, Neaton JD, Benator DA, **Vernon AA****.** In Memoriam, Fred Gordin, MD, 1951-2018. Clin Infect Dis.external icon 2018 Jun 18;67(1):153. doi: 10.1093/cid/ciy338. PMID: 29846556.
Colangeli R, Jedrey H, Kim S, Connell R, Ma S, Chippada Venkata UD, Chakravorty S, Gupta A, Sizemore EE, Diem L, Sherman DR, Okwera A, Dietze R, Boom WH, Johnson JL, Mac Kenzie WR, Alland D; DMID 01-009/Tuberculosis Trials Consortium Study 22 Teams. Bacterial Factors That Predict Relapse after Tuberculosis Therapy.external icon N Engl J Med. 2018 Aug 30;379(9):823-833. doi: 10.1056/NEJMoa1715849. PMID: 30157391.
Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D’Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O’Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.external icon Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. PMID: 30215381.
CRyPTIC Consortium and the 100,000 Genomes Project, Allix-Béguec C, Arandjelovic I, Bi L, Beckert P, Bonnet M, Bradley P, Cabibbe AM, Cancino-Muñoz I, Caulfield MJ, Chaiprasert A, Cirillo DM, Clifton DA, Comas I, Crook DW, De Filippo MR, de Neeling H, Diel R, Drobniewski FA, Faksri K, Farhat MR, Fleming J, Fowler P, Fowler TA, Gao Q, Gardy J, Gascoyne-Binzi D, Gibertoni-Cruz AL, Gil-Brusola A, Golubchik T, Gonzalo X, Grandjean L, He G, Guthrie JL, Hoosdally S, Hunt M, Iqbal Z, Ismail N, Johnston J, Khanzada FM, Khor CC, Kohl TA, Kong C, Lipworth S, Liu Q, Maphalala G, Martinez E, Mathys V, Merker M, Miotto P, Mistry N, Moore DAJ, Murray M, Niemann S, Omar SV, Ong RT, Peto TEA, Posey JE, Prammananan T, Pym A, Rodrigues C, Rodrigues M, Rodwell T, Rossolini GM, Sánchez Padilla E, Schito M, Shen X, Shendure J, Sintchenko V, Sloutsky A, Smith EG, Snyder M, Soetaert K, Starks AM, Supply P, Suriyapol P, Tahseen S, Tang P, Teo YY, Thuong TNT, Thwaites G, Tortoli E, van Soolingen D, Walker AS, Walker TM, Wilcox M, Wilson DJ, Wyllie D, Yang Y, Zhang H, Zhao Y, Zhu B. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. N Engl J Med.external icon 2018 Oct 11;379(15):1403-1415. doi: 10.1056/NEJMoa1800474. Epub 2018 Sep 26. PMID: 30280646.
Ezewudo M, Borens A, Chiner-Oms Á, Miotto P, Chindelevitch L, Starks AM, Hanna D, Liwski R, Zignol M, Gilpin C, Niemann S, Kohl TA, Warren RM, Crook D, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, McNerney R, Cirillo DM, Schito M, Rodwell TC, Posey J. Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase.external icon Sci Rep. 2018 Oct 18;8(1):15382. doi: 10.1038/s41598-018-33731-1. PMID: 30337678.
Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.external icon Lancet Respir Med. 2018 Apr;6(4):265-275. doi: 10.1016/S2213-2600(18)30078-X. PMID: 29595509.
Friedman EE, Khan A, Duffus WA. Screening for Latent Tuberculosis Infection Among HIV-Infected Medicaid Enrollees.external icon Public Health Rep. 2018 Jan 1:33354918776639. doi: 0.1177/0033354918776639. [Epub ahead of print]. PMID: 29928845.
Green KD, Biswas T, Pang AH, Willby MJ, Reed MS, Stuchlik O, Pohl J, Posey JE, Tsodikov OV, Garneau-Tsodikova S. Acetylation by Eis and Deacetylation by Rv1151c of Mycobacterium tuberculosis HupB: Biochemical and Structural Insight. Biochemistry.external icon 2018 Feb 6;57(5):781-790. doi: 10.1021/acs.biochem.7b01089. Epub 2018 Jan 18. PMID: 29345920.
Haddad MB, Raz KM, Lash TL, Hill AN, Kammerer JS, Winston CA, Castro KG, Gandhi NR, Navin TR. Simple Estimates for Local Prevalence of Latent Tuberculosis Infection, United States, 2011-2015. Emerg Infect Dis.external icon 2018 Oct;24(10):1930-1933. doi: 10.3201/eid2410.180716. PMID: 30226174.
Iqbal SA, Winston CA, Bardenheier BH, Armstrong LR, Navin TR. Age-Period-Cohort Analyses of Tuberculosis Incidence Rates by Nativity, United States, 1996-2016.external icon Am J Public Health. 2018 Nov;108(S4):S315-S320. doi: 10.2105/AJPH.2018.304687. PMID: 30383432.
Kandler JL, Mercante AD, Dalton TL, Ezewudo MN, Cowan LS, Burns SP, Metchock B; Global PETTS Investigators, Cegielski P, Posey JE. Validation of novel <i>Mycobacterium tuberculosis</i> isoniazid resistance mutations not detectable by common molecular tests.external icon Antimicrob Agents Chemother. 2018 Aug 6. pii: AAC.00974-18. doi: 10.1128/AAC.00974-18. [Epub ahead of print]. PMID: 30082293.
Khan A, Marks S, Katz D, Morris SB, Lambert L, Magee E, Bowman S, Grant G. Changes in Tuberculosis Disparities at a Time of Decreasing Tuberculosis Incidence in the United States, 1994-2016.external icon Am J Public Health. 2018 Nov;108(S4):S321-S326. doi: 10.2105/AJPH.2018.304606. PMID: 30383425.
Lam CK, McGinnis Pilote K, Haque A, Burzynski J, Chuck C, Macaraig M. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study.external icon J Med Internet Res. 2018 Nov 20;20(11):e287. doi: 10.2196/jmir.9825. PMID: 30459146.
Lambert LA, Katz D, Feng PJ, Djojonegoro BM, Fair E, Jasuja S, Marantz S, Horsburgh CR Jr, Ho C. Impact of Choice of Test for Latent Tuberculosis Infection on Treatment Acceptance and Completion.external icon Microbiol Insights. 2018 Nov 27;11:1178636118811311. doi: 10.1177/1178636118811311. eCollection 2018. PMID: 30505150.
Lowenthal P, Lin SG, Desmond E, Shah N, Flood J, Barry PM. Evaluation of the impact of a sequencing assay for detection of drug resistance on the clinical management of tuberculosis.external icon Clin Infect Dis. 2018 Nov 1. doi: 10.1093/cid/ciy937. [Epub ahead of print]. PMID: 30383209.
Macaraig MM, Jalees M, Lam C, Burzynski J. Improved treatment completion with shorter treatment regimens for latent tuberculous infection. Int J Tuberc Lung Dis.external icon 2018 Nov 1;22(11):1344-1349. doi: 10.5588/ijtld.18.0035. PMID: 30355415.
Mase A, Ryan S, Mader G, Alvarez A, Armitige L, Chen L, McSherry G, Wilson J, **Mase S****,**Banerjee R. Pediatric tuberculosis consultations across 5 CDC regional tuberculosis training and medical consultation centers. J Clin Tuberc Other Mycobact Dis. 2018 (11):23–7.
Menzies NA, Cohen T, Hill AN, Yaesoubi R, Galer K, Wolf E, Marks SM, Salomon JA. Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model.external icon Am J Epidemiol. 2018 May 14. doi: 10.1093/aje/kwy094. [Epub ahead of print]. PMID: 29762657.
Menzies NA, Hill AN, Cohen T, Salomon JA. The impact of migration on tuberculosis in the United States.external icon Int J Tuberc Lung Dis. 2018 Dec 1;22(12):1392-1403. doi: 10.5588/ijtld.17.0185. PMID: 30606311.
Menzies NA, Wolf E, Connors D, Bellerose M, Sbarra AN, Cohen T, Hill AN, Yaesoubi R, Galer K, White PJ, Abubakar I, Salomon JA. Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions.external icon Lancet Infect Dis. 2018 Apr 10. pii: S1473-3099(18)30134-8. doi: 10.1016/S1473-3099(18)30134-8. [Epub ahead of print]. PMID: 29653698.
Moro RN, Scott NA, Vernon A, Tepper NK, Goldberg SV, Schwartzman K, Leung CC, Schluger NW, Belknap RW, Chaisson RE, Narita M, Machado ES, Lopez M, Sanchez J, Villarino ME, Sterling TR. Exposure to Latent Tuberculosis Treatment during Pregnancy: The PREVENT TB and the iAdhere Trials.external icon Ann Am Thorac Soc. 2018 Feb 2. doi: 10.1513/AnnalsATS.201704-326OC. [Epub ahead of print]. PMID: 29393655.
Mullins J, Lobato MN, Bemis K, Sosa L. Spatial clusters of latent tuberculous infection, Connecticut, 2010-2014.external icon Int J Tuberc Lung Dis. 2018 Feb 1;22(2):165-170. doi: 10.5588/ijtld.17.0223. PMID: 29506612.
Nelson KN, Shah NS, Mathema B, Ismail N, Brust JCM, Brown TS, Auld SC, Omar SV, Morris N, Campbell A, Allana S, Moodley P, Mlisana K, Gandhi NR. Spatial Patterns of Extensively drug-resistant Tuberculosis (XDR-tuberculosis) transmission in KwaZulu-Natal, South Africa.external icon J Infect Dis. 2018 Jun 28. doi: 10.1093/infdis/jiy394. [Epub ahead of print]. PMID: 29961879.
Ngo HX, Green KD, Gajadeera CS, Willby MJ, Holbrook SYL, Hou C, Garzan A, Mayhoub AS, Posey JE, Tsodikov OV, Garneau-Tsodikova S. Potent 1,2,4-Triazino[5,6 b]indole-3-thioether Inhibitors of the Kanamycin Resistance Enzyme Eis from Mycobacterium tuberculosis.external icon ACS Infect Dis. 2018 Mar 30. doi: 10.1021/acsinfecdis.8b00074. [Epub ahead of print]. PMID: 29601176.
Njie GJ, Morris SB, Woodruff RY, Moro RN, Vernon AA, Borisov AS. Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.external icon Am J Prev Med. 2018 Jun 11. pii: S0749-3797(18)31737-9. doi: 10.1016/j.amepre.2018.04.030. [Epub ahead of print]. Review. PMID: 29910114.
Parriott A, Malekinejad M, Miller AP, Horvath H, Marks SM, Kahn JG. Yield of testing and treatment for tuberculosis among foreign-born persons during contact investigations in the United States: A semi-systematic review.external icon PLoS One. 2018 Jul 19;13(7):e0200485. doi: 10.1371/journal.pone.0200485. eCollection 2018. PMID: 30024909.
Parriott A, Malekinejad M, Miller AP, Marks SM, Horvath H, Kahn JG. Care Cascade for targeted tuberculosis testing and linkage to Care in Homeless Populations in the United States: a meta-analysis.external icon BMC Public Health. 2018 Apr 12;18(1):485. doi: 10.1186/s12889-018-5393-x. PMID: 29650047.
Poghotanyan G, Feng Z, Glasser JW, Hill AN. Constrained minimization problems for the reproduction number in meta-population models. J Math Biol.external icon 2018 Feb 14. doi: 10.1007/s00285-018-1216-z. [Epub ahead of print]. PMID: 29445854.
Reaves EJ, Shah S, France AM, Morris SB, Bradley H. In Reply: Latent tuberculous infection testing among HIV-infected persons in clinical care.external icon Int J Tuberc Lung Dis. 2018 Apr 1;22(4):468-469. doi: 10.5588/ijtld.17.0910-2. No abstract available. PMID: 29563002.
Reichler MR, Khan A, Sterling TR, Zhao H, Moran J, McAuley J, Bessler P, Mangura B; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Risk and Timing of Tuberculosis Among Close Contacts of Persons with Infectious Tuberculosis.external icon J Infect Dis. 2018 May 15. doi: 10.1093/infdis/jiy265. [Epub ahead of print]. PMID: 29767733.
Schmit KM, Lobato MN, Lang SG, Wheeler S, Kendig NE, Bur S. High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons.external icon J Public Health Manag Pract. 2018 Jul 17. doi: 10.1097/PHH.0000000000000822. [Epub ahead of print]. PMID: 30024493.
Shah NS, Westenhouse J, Lowenthal P, Schecter G, True L, Mase S, Barry PM, Flood J. The California Multidrug-Resistant Tuberculosis Consult Service: a partnership of state and local programs.external icon Public Health Action. 2018 Mar 21;8(1):7-13. doi: 10.5588/pha.17.0091. PMID: 29581937.
Shete PB, Boccia D, Dhavan P, Gebreselassie N, Lönnroth K, Marks S, Matteelli A, Posey DL, van der Werf MJ, Winston CA, Lienhardt C. Defining a migrant-inclusive tuberculosis research agenda to end TB.external icon Int J Tuberc Lung Dis. 2018 Aug 1;22(8):835-843. doi: 10.5588/ijtld.17.0503. PMID: 29991390.
Stafford C, Atkinson-Dunn R, Buss SN, Dalton T, Gibson D, Johnston S, King E, Grace Lin SY, Mitchell KK, Murtaugh WA, Sease H, Southern TR, Tans-Kersten JL, Travanty EA, Triplett LR, Wroblewski K, Starks AM. The Use of a Shared Services Model for Mycobacteriology Testing: Lessons Learned.external icon Public Health Rep. 2018 Jan/Feb;133(1):93-99. doi: 10.1177/0033354917743498. Epub 2017 Dec 19. PMID: 29258383.
Stockbridge EL, Miller TL, Carlson EK, Ho C. Predictors of latent tuberculosis infection treatment completion in the US private sector: an analysis of administrative claims data.external icon BMC Public Health. 2018 May 29;18(1):662. doi: 10.1186/s12889-018-5578-3. PMID: 29843664.
Stockbridge EL, Miller TL, Carlson EK, Ho C. Private sector tuberculosis prevention in the US: Characteristics associated with interferon-gamma release assay or tuberculin skin testing.external icon PLoS One. 2018 Mar 28;13(3):e0193432. doi: 10.1371/journal.pone.0193432. eCollection 2018. PMID: 29590130.
Stout JE, Belknap R, Wu YJ, Ho CS. Paradox of serial interferon-gamma release assays: variability width more important than specificity size.external icon Int J Tuberc Lung Dis. 2018 May 1;22(5):518-523. doi: 10.5588/ijtld.17.0650. PMID: 29663956.
Stout JE, Wu Y, Ho CS, Pettit AC, Feng PJ, Katz DJ, Ghosh S, Venkatappa T, Luo R; Tuberculosis Epidemiologic Studies Consortium. Evaluating latent tuberculosis infection diagnostics using latent class analysis.external icon Thorax. 2018 Jul 7. pii: thoraxjnl-2018-211715. doi: 10.1136/thoraxjnl-2018-211715. [Epub ahead of print]. PMID: 29982223.
Suragh TA, Lewis P, Arana J, Mba-Jonas A, Li R, Stewart B, Shimabukuro TT, Cano M. Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS), 2009-2017. Br J Clin Pharmacol. 2018 Sep 19. doi: 10.1111/bcp.13736. [Epub ahead of print]. PMID: 30229993.
Weiner M, Gelfond J, Johnson-Pais TL, Engle M, Peloquin CA, Johnson JL, Sizemore EE, Mac Kenzie WR; Pharmacokinetics/Pharmacodynamics Group of Tuberculosis Trials Consortium. Elevated Plasma Moxifloxacin Concentrations and <i>SLCO1B1</i> g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.external icon Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.01802-17. doi: 10.1128/AAC.01802-17. [Epub ahead of print]. PMID: 29463526.
Woodruff RSY, Miner MC, Miramontes R. Development of a Surveillance Definition for United States-Mexico Binational Cases of Tuberculosis.external icon Public Health Rep. 2018 Mar/Apr;133(2):155-162. doi: 10.1177/0033354918760575. PMID: 29570435.
Wortham JM. TB Anywhere is TB Everywhere.external icon Isr J Health Policy Res. 2018 Jul 20;7(1):40. doi: 10.1186/s13584-018-0233-0. PMID: 30029612.

*Last updated May 9, 2019*
							
					
						Page last reviewed:  May 9, 2019										Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue